$Cardioprotective efficacy of Xin-shu-bao tablet in heart failure with reduced ejection fraction by modulating THBD/ARRB1/FGF1/STIM1 signaling$

Cardioprotective efficacy of Xin-shu-bao tablet in heart failure with reduced ejection fraction by modulating THBD/ARRB1/FGF1/STIM1 signaling

Traditional Chinese medicine offer unique advantages in mitigating and preventing early or intermediate stage for treating heart failure (HF). The purpose of this study was to assess the in vivo therapeutic efficacy of Xin-shu-bao (XSB) at different stages of HF following induction of a myocardial i...

Full description

Bibliographic Details
Main Authors:	Fengrong Zhang, Xingyue Xu, Jinli Hou, Honghe Xiao, Feifei Guo, Xianyu Li, Hongjun Yang
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	HFrEF Xin-shu-bao tablet Cardiac hypertrophy Cardiac fibrosis Fibroblast growth factor 1 Arrestin β1
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332223009101

Similar Items

Cardiac Contractility Modulation in Patients with Heart Failure with Reduced Left Ventricular Ejection Fraction
by: Francesco Giallauria, et al.
Published: (2021-03-01)

Standardized Xin-Ke-Shu tablets improves the disturbances of lipid, energy, and amino acid metabolism in a rabbit model of atherosclerosis
by: Yong Yang, et al.
Published: (2019-01-01)

Reversible Thiol Oxidation Increases Mitochondrial Electron Transport Complex Enzyme Activity but Not Respiration in Cardiomyocytes from Patients with End-Stage Heart Failure
by: Ravi A. Kumar, et al.
Published: (2022-07-01)

The Evolution of Mathematics in Ancient China: From the newly discovered 數 Shu and 算數書 Suan Shu Shu Bamboo Texts to the Nine Chapters on the Art of Mathematics
by: Joseph W. Dauben
Published: (2020-10-01)

Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p
by: Celestino Sardu, et al.
Published: (2023-01-01)

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials
by: Nitish K. Dhingra, et al.
Published: (2021-12-01)

Exercise training and high‐sensitivity cardiac troponin‐I in patients with heart failure with reduced ejection fraction
by: Egil Riveland, et al.
Published: (2024-04-01)

Aging Impairs Reverse Remodeling and Recovery of Ventricular Function after Isoproterenol-Induced Cardiomyopathy
by: Laia Yáñez-Bisbe, et al.
Published: (2021-12-01)

Upgrading to cardiac resynchronisation therapy: Concordance of real-world experience with clinical guidelines
by: Laura Tan, et al.
Published: (2021-04-01)

T1 and T2 mapping to detect chronic inflammation in cardiac magnetic resonance imaging in heart failure with reduced ejection fraction
by: Tilman Emrich, et al.
Published: (2020-10-01)

Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies
by: Erberto Carluccio, et al.
Published: (2023-09-01)

Prognostic value of mean velocity at the pulmonary artery estimated by cardiovascular magnetic resonance as a prognostic predictor in a cohort of patients with new-onset heart failure with reduced ejection fraction
by: Blanca Trejo-Velasco, et al.
Published: (2020-04-01)

PUFA Supplementation and Heart Failure: Effects on Fibrosis and Cardiac Remodeling
by: Francesca Oppedisano, et al.
Published: (2021-08-01)

The Sub-Analysis of HFmrEF and HFrEF Group in CORE-HF Registry : When being Good is Not Enough
by: Irnizarifka Irnizarifka, et al.
Published: (2023-10-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
by: Younan Yao, et al.
Published: (2020-12-01)

Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial
by: Fahmida Ilyas, et al.
Published: (2021-10-01)

Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
by: Judit Simon, et al.
Published: (2019-06-01)

Does Patient Compliance Influence Wearable Cardioverter Defibrillator Effectiveness? A Single-Center Experience
by: Luca Fazzini, et al.
Published: (2023-07-01)

Sex‐specific cardiovascular protein levels and their link with clinical outcome in heart failure
by: Marie deBakker, et al.
Published: (2024-02-01)

Proteomic Associations of Adverse Outcomes in Human Heart Failure
by: Marie‐Joe Dib, et al.
Published: (2024-03-01)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Gregor Poglajen, et al.
Published: (2020-07-01)

The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction
by: Michele Correale, et al.
Published: (2023-06-01)

Sex-based differences in cardiovascular proteomic profiles and their associations with adverse outcomes in patients with chronic heart failure
by: Marie de Bakker, et al.
Published: (2023-05-01)

Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)
by: Przemysław Żelazny, et al.
Published: (2022-09-01)

Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer
by: Henrike Arfsten, et al.
Published: (2021-10-01)

An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation
by: Georg Spinka, et al.
Published: (2020-11-01)

The Prognostic Value of Right Ventricular Function in Patients with Chronic Heart Failure—A Prospective Study
by: Nora Schwegel, et al.
Published: (2024-03-01)

Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up
by: Łukasz Wołowiec, et al.
Published: (2024-12-01)

sST2 and Heart Failure—Clinical Utility and Prognosis
by: Magdalena Dudek, et al.
Published: (2023-04-01)

A Simple Risk Score Based on Routine Clinical Parameters Can Predict Frailty in Hospitalized Heart Failure Patients
by: Marta Kałużna-Oleksy, et al.
Published: (2021-12-01)

Obesity and Uncontrolled Diabetes Predict Depression in HF Patients
by: Albenita Fetahu, et al.
Published: (2021-11-01)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
by: Dan Liu, et al.
Published: (2023-04-01)

Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments
by: Matthias Naegele, et al.
Published: (2016-02-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
by: Arjun K. Pandey, et al.
Published: (2022-04-01)

Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence
by: Nathanael Wood, et al.
Published: (2021-02-01)

Comparison of procedural outcomes in patients undergoing catheter vs surgical ablation for atrial fibrillation and heart failure with reduced ejection fraction
by: Rajkumar Doshi, et al.
Published: (2021-02-01)

Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis
by: Verena Tscholl, et al.
Published: (2021-08-01)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature [version 1; peer review: 2 approved]
by: Chanavuth Kanitsoraphan, et al.
Published: (2021-01-01)

Investigation of the Effect of the Degree of Processing of Radix Rehmanniae Preparata (Shu Dihuang) on Shu Dihuangtan Carbonization Preparation Technology
by: Xianglong Meng, et al.
Published: (2017-07-01)